Eisai: Lennox-Gastaut syndrome Market to Expand Significantly by 2034, States DelveInsight Report | Takeda, Ovid, SK Life Science, Epygenix, CuroNZ Ltd, Eisai

The Lennox-Gastaut syndrome market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Lennox-Gastaut syndrome pipeline products will significantly revolutionize the Lennox-Gastaut syndrome market dynamics. DelveInsight's "Lennox-Gastaut syndrome Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Lennox-Gastaut syndrome, historical and forecasted epidemiology as well as the Lennox-Gastaut syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Lennox-Gastaut syndrome market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. To Know in detail about the Lennox-Gastaut syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Lennox-Gastaut syndrome Market Forecast Some of the key facts of the Lennox-Gastaut syndrome Market Report: The Lennox-Gastaut syndrome market size was valued ~596 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034) In June 2024, UCB, a global biopharmaceutical company, announced that Epilepsia published results from a comprehensive scoping review evaluating the effectiveness of FINTEPLA® (fenfluramine) in reducing the frequency of generalized tonic-clonic seizures (GTCS) and tonic-clonic seizures (TCS) in patients with developmental and epileptic encephalopathies (DEEs). The review demonstrated a significant reduction in both GTCS and TCS across various DEEs, further supporting the data from the FINTEPLA clinical trial program. FINTEPLA is approved by the U.S. Food and Drug Administration (FDA) for treating seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients aged two years and older. In June 2024, Takeda (TSE:4502/NYSE:TAK) has announced topline results from its SKYLINE and SKYWAY studies. SKYLINE (TAK-935-3001) was a multicenter, randomized, double-blind Phase 3 trial that assessed soticlestat (TAK-935) in combination with standard care versus placebo plus standard care in patients with refractory Dravet syndrome (DS). While soticlestat did not meet the primary endpoint of reducing convulsive seizure frequency compared to placebo (p-value = 0.06), it showed clinically meaningful and nominally significant results in six key secondary endpoints, including responder rates, caregiver and clinician global impressions of improvement, and seizure intensity and duration scales during the 16-week treatment period (all p-values ≤ 0.008). DelveInsight's analysis forecasts that the Lennox-Gastaut Syndrome market will expand at a CAGR of 4.5% from 2024 to 2034. According to DelveInsight's epidemiology model, there were approximately 115,000 prevalent cases of Lennox-Gastaut Syndrome in the 7MM in 2023. This figure is expected to increase over the forecast period (2024-2034), largely due to heightened awareness and advancements in diagnostic methods. In 2023, the diagnosed prevalent cases of Lennox-Gastaut Syndrome across the 7MM totaled approximately 81,000. This number is expected to increase throughout the forecast period. In 2023, the United States recorded the highest number of diagnosed prevalent cases of Lennox-Gastaut Syndrome, with around 34,000 cases, a figure projected to rise throughout the forecast period. In 2023, the diagnosed prevalent cases of Lennox-Gastaut Syndrome in the US were distributed by gender, with males representing about 25,000 cases and females accounting for approximately 9,000 cases. In 2023, among the EU4 and the UK, Germany recorded the highest number of diagnosed prevalent cases of Lennox-Gastaut Syndrome, with roughly 11,000 cases. France followed with approximately 9,600 cases, and Italy had around 8,800 cases. In 2023, Japan had the fewest diagnosed prevalent cases of Lennox-Gastaut Syndrome, with around 3,000 cases. Key Lennox-Gastaut syndrome Companies: Takeda /Ovid, SK Life Science, Inc., Epygenix, CuroNZ Ltd, Eisai, and others Key Lennox-Gastaut syndrome Therapies: Soticlestat, Carisbamate, EPX-100, NRP2945, Fycompa, TAK-935/OV935 (Soticlestat), and others The Lennox-Gastaut syndrome epidemiology based on gender analyzed that Lennox-Gastaut syndrome is found to be more prevalent in males than in females, for some undefined reason, with the male to female ratio being 1:6 (relative risk, 5.31). The Lennox-Gastaut syndrome market size was valued ~596 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034) In June 2024, UCB, a global biopharmaceutical company, announced that Epilepsia published results from a comprehensive scoping review evaluating the effectiveness of FINTEPLA® (fenfluramine) in reducing the frequency of generalized tonic-clonic seizures (GTCS) and tonic-clonic seizures (TCS) in patients with developmental and epileptic encephalopathies (DEEs). The review demonstrated a significant reduction in both GTCS and TCS across various DEEs, further supporting the data from the FINTEPLA clinical trial program. FINTEPLA is approved by the U.S. Food and Drug Administration (FDA) for treating seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients aged two years and older. In June 2024, Takeda (TSE:4502/NYSE:TAK) has announced topline results from its SKYLINE and SKYWAY studies. SKYLINE (TAK-935-3001) was a multicenter, randomized, double-blind Phase 3 trial that assessed soticlestat (TAK-935) in combination with standard care versus placebo plus standard care in patients with refractory Dravet syndrome (DS). While soticlestat did not meet the primary endpoint of reducing convulsive seizure frequency compared to placebo (p-value = 0.06), it showed clinically meaningful and nominally significant results in six key secondary endpoints, including responder rates, caregiver and clinician global impressions of improvement, and seizure intensity and duration scales during the 16-week treatment period (all p-values ≤ 0.008). DelveInsight's analysis forecasts that the Lennox-Gastaut Syndrome market will expand at a CAGR of 4.5% from 2024 to 2034. According to DelveInsight's epidemiology model, there were approximately 115,000 prevalent cases of Lennox-Gastaut Syndrome in the 7MM in 2023. This figure is expected to increase over the forecast period (2024-2034), largely due to heightened awareness and advancements in diagnostic methods. In 2023, the diagnosed prevalent cases of Lennox-Gastaut Syndrome across the 7MM totaled approximately 81,000. This number is expected to increase throughout the forecast period. In 2023, the United States recorded the highest number of diagnosed prevalent cases of Lennox-Gastaut Syndrome, with around 34,000 cases, a figure projected to rise throughout the forecast period. In 2023, the diagnosed prevalent cases of Lennox-Gastaut Syndrome in the US were distributed by gender, with males representing about 25,000 cases and females accounting for approximately 9,000 cases. In 2023, among the EU4 and the UK, Germany recorded the highest number of diagnosed prevalent cases of Lennox-Gastaut Syndrome, with roughly 11,000 cases. France followed with approximately 9,600 cases, and Italy had around 8,800 cases. In 2023, Japan had the fewest diagnosed prevalent cases of Lennox-Gastaut Syndrome, with around 3,000 cases. Key Lennox-Gastaut syndrome Companies: Takeda /Ovid, SK Life Science, Inc., Epygenix, CuroNZ Ltd, Eisai, and others Key Lennox-Gastaut syndrome Therapies: Soticlestat, Carisbamate, EPX-100, NRP2945, Fycompa, TAK-935/OV935 (Soticlestat), and others The Lennox-Gastaut syndrome epidemiology based on gender analyzed that Lennox-Gastaut syndrome is found to be more prevalent in males than in females, for some undefined reason, with the male to female ratio being 1:6 (relative risk, 5.31). Lennox-Gastaut syndrome Overview Lennox-Gastaut syndrome (LGS) is a rare and severe form of epilepsy that typically begins in early childhood, often between ages 3 and 5. It is characterized by multiple types of seizures, including tonic (stiffening) and atonic (loss of muscle tone) seizures. People with LGS also experience developmental delays, cognitive impairments, and behavioral issues. The causes of LGS can vary, including genetic factors, brain injury, or other underlying conditions. Treatment usually involves a combination of medications, and in some cases, surgery or dietary therapies, to manage the seizures and improve quality of life. Get a Free sample for the Lennox-Gastaut syndrome Market Report - https://www.delveinsight.com/report-store/lennox-gastaut-syndrome-market Lennox-Gastaut syndrome Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Lennox-Gastaut syndrome Epidemiology Segmentation: The Lennox-Gastaut syndrome market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into: Total Prevalent Cases of Lennox-Gastaut syndrome in the 7MM Total Diagnosed Prevalent Cases of Lennox-Gastaut syndrome in the 7MM Gender-specific Diagnosed Prevalent Cases of Lennox-Gastaut syndrome in the 7MM Seizures-specific Diagnosed Prevalent Cases of Lennox Gastaut syndrome in the 7MM Total Prevalent Cases of Lennox-Gastaut syndrome in the 7MM Total Diagnosed Prev